PMID- 17278421
OWN - NLM
STAT- MEDLINE
DCOM- 20070831
LR  - 20141120
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 27
IP  - 9
DP  - 2006 Sep
TI  - [Antithrombotic mechanisms of holothurian glycosaminoglycan extracted from sea 
      cucumber].
PG  - 579-83
AB  - OBJECTIVE: To investigate the antithrombotic mechanisms of holothurian 
      glycosaminoglycan (GAG) extracted from sea cucumber. METHODS: Human endothelial 
      cell line EA. hy926 cells were treated with 10 mg/L GAG or 10U/mL unfractionated 
      heparin (UFH) by short-term (15 min - 2 h) and longer-time incubation (6 h - 48 
      h). Different doses of GAG were used to stimulate EA. hy926. Released free tissue 
      factor pathway inhibitor(TFPI) was determined by ELISA assay. TFPI expression was 
      investigated by immunofluorescent method and TFPI mRNA level by real-time PCR. In 
      a 96-wells microtitre plate, pooled normal plasma containing different 
      concentrations of GAG was allowed to clot by addition of thrombin and calcium 
      chloride, fibrinolysis was induced by addition of t-PA. TRR (TAFI-related 
      retardation of clot lysis) was used to assess thrombin-activatable fibrinolysis 
      inhibitor(TAFI) functional activity. RESULTS: GAG increased TFPI synthesis, 
      expression and secretion in a dose- and time dependent manner. GAG at low 
      concentrations could lengthen while at intermediate concentrations could shorten 
      clot lysis times significantly as compared to control values. TRR was 
      dose-dependently decreased on addition of GAG. CONCLUSIONS: GAG increases TFPI 
      synthesis, expression and secretion of endothelial cells. GAG at intermediate 
      concentrations significantly affects clot stability of a developing clot by means 
      of diminishing TAFI activation.
FAU - Shen, Wei-Zhang
AU  - Shen WZ
AD  - Shanghai Institute of Haematology, Ruijin Hospital, Shanghai Jiaotong University, 
      Shanghai 200025, China.
FAU - Zhou, Rong-Fu
AU  - Zhou RF
FAU - Wang, Xue-Feng
AU  - Wang XF
FAU - Ding, Qiu-Lan
AU  - Ding QL
FAU - Wang, Hong-Li
AU  - Wang HL
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Lipoproteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tissue Extracts)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.17.20 (Carboxypeptidase B2)
SB  - IM
MH  - Animals
MH  - Carboxypeptidase B2/antagonists & inhibitors
MH  - Cell Line
MH  - Dose-Response Relationship, Drug
MH  - Endothelial Cells/*drug effects/metabolism
MH  - Glycosaminoglycans/*pharmacology
MH  - Heparin/pharmacology
MH  - *Holothuria
MH  - Humans
MH  - Lipoproteins/*biosynthesis/genetics
MH  - RNA, Messenger/genetics
MH  - Tissue Extracts/*pharmacology
EDAT- 2007/02/07 09:00
MHDA- 2007/09/01 09:00
CRDT- 2007/02/07 09:00
PHST- 2007/02/07 09:00 [pubmed]
PHST- 2007/09/01 09:00 [medline]
PHST- 2007/02/07 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2006 Sep;27(9):579-83.